skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

About Dean

UK

+5 year(s) experience

Dean_Rudge_Pharma_Intelligence
Joining the Generics bulletin team in 2013, Dean has five years of experience reporting on the global generic, biosimilar and value-added medicines industries.
Dean has built up a wealth of knowledge on the global generics and biosimilar medicines industries in his five years with Generics bulletin. He specializes in commercial and legal issues, writing in-depth analyses of corporate strategy and getting under the skin of patent infringement proceedings and other litigation. He attends investor and regulatory meetings with business leaders, favoring the investor days with their focus on corporate strategy. In his spare time, Dean enjoys visiting museums and playing five-a-side football.

Analyst Articles

Articles by Dean

  • Generics Bulletin

    Coronavirus Puts The Brakes On Mylan-Upjohn Merger

    Coronavirus Puts The Brakes On Mylan-Upjohn Merger logo

    Mylan and Pfizer’s Upjohn were all set to merge into Viatris by midway through this year, subject to certain approvals, but that will now not happen in that timeframe as the global coronavirus pandemic proves an insurmountable barrier to getting the deal over the line.  

    Topic Coronavirus

  • Generics Bulletin

    Sandoz, Teva And Mylan Step Up On Hydroxychloroquine

    Donald Trump

    To meet expected demand in the weeks and months ahead, Novartis' Sandoz has committed to donate up to 130 million doses of generic hydroxychloroquine – a treatment for malaria currently under investigation as a therapy to aid in the COVID-19 pandemic – while Teva and Mylan have also made strides, as the generics industry continues to play its part in tackling the coronavirus outbreak.

    Topic Coronavirus